Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Enhanced absorption of insulin aspart as the result of a dispersed injection strategy tested in a randomized trial in type 1 diabetic patients.

Mader JK, Birngruber T, Korsatko S, Deller S, Köhler G, Boysen S, Augustin T, Mautner SI, Sinner F, Pieber TR; AP@home Consortium.

Diabetes Care. 2013 Apr;36(4):780-5. doi: 10.2337/dc12-1319. Epub 2012 Nov 27.

2.

Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart.

Heise T, Hövelmann U, Brøndsted L, Adrian CL, Nosek L, Haahr H.

Diabetes Obes Metab. 2015 Jul;17(7):682-8. doi: 10.1111/dom.12468. Epub 2015 May 8.

3.

Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device.

Cengiz E, Weinzimer SA, Sherr JL, Tichy E, Martin M, Carria L, Steffen A, Tamborlane WV.

Pediatr Diabetes. 2013 May;14(3):168-73. doi: 10.1111/pedi.12001. Epub 2012 Oct 28.

4.
5.

The alteration of aspart insulin pharmacodynamics when mixed with detemir insulin.

Cengiz E, Swan KL, Tamborlane WV, Sherr JL, Martin M, Weinzimer SA.

Diabetes Care. 2012 Apr;35(4):690-2. doi: 10.2337/dc11-0732. Epub 2012 Feb 28.

6.

Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial.

Ruan Y, Elleri D, Allen JM, Tauschmann M, Wilinska ME, Dunger DB, Hovorka R.

Diabetologia. 2015 Apr;58(4):687-90. doi: 10.1007/s00125-014-3483-6. Epub 2014 Dec 24.

7.

A pilot study to examine the tolerability and device preference in type 1 diabetes of insulin aspart administered by InsuJet compared with subcutaneous injection.

Reutens AT, Balkau B, Cohen N.

Diabetes Technol Ther. 2014 Apr;16(4):235-40. doi: 10.1089/dia.2013.0250. Epub 2013 Nov 28.

PMID:
24286115
8.

Improved pharmacokinetic and pharmacodynamic profiles of insulin analogues using InsuPatch, a local heating device.

Landau Z, Klonoff D, Nayberg I, Feldman D, Levit SB, Lender D, Mosenzon O, Raz I, Wainstein J.

Diabetes Metab Res Rev. 2014 Nov;30(8):686-92. doi: 10.1002/dmrr.2536.

PMID:
24610683
10.

A comparison of the pharmacodynamic profiles of jet-injected regular human insulin versus conventionally administered insulin aspart in healthy volunteers.

Engwerda EE, Tack CJ, de Galan BE.

Diabetes Res Clin Pract. 2016 Nov;121:86-90. doi: 10.1016/j.diabres.2016.09.001. Epub 2016 Sep 8.

PMID:
27662042
11.

Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin.

Rosenfalck AM, Thorsby P, Kjems L, Birkeland K, Dejgaard A, Hanssen KF, Madsbad S.

Acta Diabetol. 2000 Mar;37(1):41-6.

PMID:
10928235
12.

Faster in and faster out: accelerating insulin absorption and action by insulin infusion site warming.

Cengiz E, Weinzimer SA, Sherr JL, Tichy EM, Carria L, Cappiello D, Steffen A, Tamborlane WV.

Diabetes Technol Ther. 2014 Jan;16(1):20-5. doi: 10.1089/dia.2013.0187. Epub 2013 Dec 24.

13.

A comparison of pharmacokinetics and pharmacodynamics of insulin aspart, biphasic insulin aspart 70, biphasic insulin aspart 50, and human insulin: a randomized, quadruple crossover study.

Ma Z, Parkner T, Frystyk J, Laursen T, Lauritzen T, Christiansen JS.

Diabetes Technol Ther. 2012 Jul;14(7):589-95. doi: 10.1089/dia.2011.0299. Epub 2012 Apr 20.

PMID:
22519735
14.

Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus.

Heise T, Nosek L, Klein O, Coester H, Svendsen AL, Haahr H.

Diabetes Obes Metab. 2015 Jul;17(7):659-64. doi: 10.1111/dom.12463. Epub 2015 May 1.

PMID:
25772444
15.

The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study.

Heise T, Eckers U, Kanc K, Nielsen JN, Nosek L.

Diabetes Technol Ther. 2008 Dec;10(6):479-85. doi: 10.1089/dia.2008.0019.

PMID:
19049377
16.

Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection.

Pettis RJ, Ginsberg B, Hirsch L, Sutter D, Keith S, McVey E, Harvey NG, Hompesch M, Nosek L, Kapitza C, Heinemann L.

Diabetes Technol Ther. 2011 Apr;13(4):435-42. doi: 10.1089/dia.2010.0184. Epub 2011 Feb 28.

PMID:
21355718
17.
18.

Inhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week Trial.

Bode BW, McGill JB, Lorber DL, Gross JL, Chang PC, Bregman DB; Affinity 1 Study Group.

Diabetes Care. 2015 Dec;38(12):2266-73. doi: 10.2337/dc15-0075. Epub 2015 Jul 15.

PMID:
26180109
19.
20.

Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions.

Hövelmann U, Heise T, Nosek L, Sassenfeld B, Thomsen KMD, Haahr H.

Clin Drug Investig. 2017 May;37(5):503-509. doi: 10.1007/s40261-017-0499-y.

Supplemental Content

Support Center